Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4647181 | 0.98 | MAPT (0.60) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL13875704 | 0.81 | ADORA1 (0.58) | MAPTAGTR1ADORA2AADORA1KMT2A | |
| SCHEMBL10039374 | 0.80 | KMT2A (0.60) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL10329709 | 0.80 | HRH4 (0.70) | MAPTTP53LMNAAGTR1HRH4 | |
| SCHEMBL416616 | 0.79 | MEN1 (0.66) | MAPTTP53LMNAGAAAGTR1 | |
| SCHEMBL12907710 | 0.77 | MAPT (1.00) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL8378094 | 0.77 | TP53 (0.39) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL16353106 | 0.77 | KMT2A (0.60) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL17286932 | 0.77 | KMT2A (0.60) | MAPTTP53LMNAPOLBGAA | |
| SCHEMBL8265150 | 0.76 | ADORA2A (0.66) | MAPTTP53LMNAPOLBAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288398-B2 | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones | MERCK SERONO SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288398-B2 | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones | MERCK SERONO SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288398-B2 | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones | MERCK SERONO SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| EP-1957469-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | Laboratoires Serono SA (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065940-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | LABORATOIRES SERONO S.A. (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065940-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | LABORATOIRES SERONO S.A. (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | TYMP, DHFR, DPYD | MAPT 4664/4885TP53 105/4885LMNA 3685/4885 |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | TYMP, DHFR, DPYD | MAPT 4664/4885TP53 105/4885LMNA 3685/4885 |
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | MAPT 699/4885TP53 2020/4885LMNA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.